Shionogi
Japanese pharmaceutical company
title: "Shionogi" type: doc version: 1 created: 2026-02-28 author: "Wikipedia contributors" status: active scope: public tags: ["biotechnology-companies-of-japan", "companies-listed-on-the-osaka-exchange", "companies-listed-on-the-tokyo-stock-exchange", "companies-in-the-nikkei-225", "japanese-brands", "manufacturing-companies-based-in-osaka", "pharmaceutical-companies-established-in-1878", "pharmaceutical-companies-of-japan", "covid-19-vaccine-producers"] description: "Japanese pharmaceutical company" topic_path: "geography/japan" source: "https://en.wikipedia.org/wiki/Shionogi" license: "CC BY-SA 4.0" wikipedia_page_id: 0 wikipedia_revision_id: 0
::summary Japanese pharmaceutical company ::
::data[format=table title="Infobox company"]
| Field | Value |
|---|---|
| name | Shionogi & Co., Ltd. |
| type | Public (K.K) |
| native_name | 塩野義製薬株式会社 |
| native_name_lang | ja |
| romanized_name | Shionogi Seiyaku Kabushiki Kaisha |
| founder | Gisaburo Shiono Sr. |
| foundation | Osaka, Japan () |
| num_employees | Consolidated : 6,082 |
| industry | Biotechnology & Pharmaceuticals |
| products | |
| key_people | |
| traded_as | |
| Nikkei 225 Component | |
| homepage | |
| location | 1-8, Doshomachi 3-chome, Chuo-ku, Osaka 541-0045, Japan |
| logo | SHIONOGI Top-logo-03.png |
| subsid | Shinogi Healthcare |
| Shinogi Pharma | |
| UMN Pharma | |
| revenue | ¥ 426.684 billion (2022) |
| operating_income | ¥ 133.274 billion (2022) |
| net_income | ¥ 107.367 billion (2022) |
| assets | ¥ 768.120 billion (2022) |
| equity | ¥ 1,121.878 billion (2022) |
| footnotes | |
| :: |
| name = Shionogi & Co., Ltd. | type = Public (K.K) | native_name = 塩野義製薬株式会社 | native_name_lang = ja | romanized_name = Shionogi Seiyaku Kabushiki Kaisha | founder = Gisaburo Shiono Sr. | foundation = Osaka, Japan () | num_employees = Consolidated : 6,082 | industry = Biotechnology & Pharmaceuticals | products = | key_people = | traded_as = Nikkei 225 Component | homepage = | location = 1-8, Doshomachi 3-chome, Chuo-ku, Osaka 541-0045, Japan | logo = SHIONOGI Top-logo-03.png | subsid = Shinogi Healthcare Shinogi Pharma UMN Pharma | revenue = ¥ 426.684 billion (2022) | operating_income = ¥ 133.274 billion (2022) | net_income = ¥ 107.367 billion (2022) | assets = ¥ 768.120 billion (2022) | equity = ¥ 1,121.878 billion (2022) | footnotes =
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana (シオノギ).
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough (merged in 2009 with Merck & Co) to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m.
Medicines
Released
- Avelox, antibacterial antiseptic that treats a number of infections.
- Claritin, An anti-histamine marketed in alliance with Schering-Plough.
- Crestor, cholesterol drug [[Image:Shionogi.JPG|thumb|right|Shionogi Headquarters in Osaka|315x315px]], marketing rights sold to AstraZeneca in 1998.
- Cymbalta, an SNRI class anti-depressant, marketed in alliance with Eli Lilly.
- Differin (developed by Galderma), a topical retinoid for acne, marketed in Japan in alliance with Galderma.
- Fortamet
- Methylin
- Mogadon, a short-term treatment for insomnia.
- Mulpleta, a thrombopoietin receptor agonist.
- Osphena, an estrogen receptor agonist, marketing rights sold to Duchesnay in 2017.
- Symproic, a μ-opioid receptor antagonist, for opioid-induced constipation treatment.
- Xofluza, an endonuclease inhibitor, for influenza treatment.
- Ensitrelvir, the first Japanese domestic pill to treat COVID-19.
Under development
- (BGE-175), a DP1 receptor antagonist under development for treatment of COVID-19 in elderly patients and allergic rhinitis.
Media
- Shionogi (and later Shinonogi Healthcare) has been the sponsor of Fuji Television Network, Inc.'s "Music Fair" since it started in 1964. In January 2025, Shionogi has decided to remove its name from the show, due to the Fuji TV - Masahiro Nakai scandal. A Shionogi representative said in an interview, "I believe that Fuji Television should provide an explanation of the facts and future actions as soon as possible".
- Shionogi was a main sponsor of Team Lotus in the team's final years between 1991 and 1994.
References
References
- "Shionogi Company Profile".
- "Shionogi Annual Report 2013".
- (23 February 2023). "Consolidated Financial Results for Fiscal Year 2022 (IFRS)".
- "Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio". viivhealthcare.com.
- "Components:Nikkei Stock Average". [[Nikkei Inc.]].
- BioSpace. (27 June 2023). "Shionogi buys Qpex Biopharma for $140M, expands antimicrobial pipeline – PharmaLive". PharmaLive.
- Du, Lisa. (7 October 2021). "Covid Pill Sales Could Hit $2 Billion, Japan's Shionogi Says". [[Bloomberg News.
- Du, Lisa. (22 February 2010). "AstraZeneca begins court fight over Crestor patent". [[Reuters]].
- (March 10, 2017). "Duchesnay acquires Osphena from Shionogi Inc.". Duchesnay.
- (25 February 2022). "Japan's Shionogi seeks approval for COVID-19 pill". Reuters.
- "Notice regarding an initiation of Phase 2 clinical trial by BioAge aimed at treating older patients of COVID-19".
- "Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory Failure". [[ClinicalTrials.gov]].
- (21 March 2022). "Eicosanoid signaling blockade protects middle-aged mice from severe COVID-19". [[Nature (journal).
- Swift, Rocky. (26 January 2021). "Japan's Shionogi sells coronavirus drug rights to U.S. biotech BioAge".
- "New BioAge Drug Prevents Death From COVID-19 in Old Mice by Reversing Immune Aging". BioAge Labs.
- (22 January 2025). "[naka kōka] continúa la crisis en Fuji TV".
- (21 January 2025). "塩野義、番組から社名削除を検討 フジのミュージックフェア".
- Perry, Alan. "Sponsor Company Profiles <!--".
::callout[type=info title="Wikipedia Source"] This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page. ::